Navigation Links
Breakthrough AffloVest now reimbursed by Medicare and private health insurance
Date:9/10/2013

AUSTIN, Texas, Sept. 10, 2013 /PRNewswire/ -- AffloVest, the first-ever portable High Frequency Chest Wall Oscillation (HFCWO) vest, is now approved for Medicare and private health insurance reimbursement.  Millions of Americans with respiratory disease can benefit from the innovative new airway clearance therapy vest that dramatically improves cough productivity and ease of breathing for chronic lung conditions such as severe Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis, Cystic Fibrosis and other related ailments.

The AffloVest recently earned FDA 510k market clearance in the United States and HCPCS reimbursement codes, according to David Shockley, President of International Biophysics Corporation (IBC), which developed and now markets the product in the U.S.

"With both Medicare and private health insurance reimbursement approved for AffloVest, this breakthrough technology is affordably available to millions of patients now," Shockley said.  "Other airway clearance vests tether the patient by an air hose to bulky machines that must be plugged into a wall.  The AffloVest is the market's first portable, battery-operated HFCWO vest. Users can move about freely – even travel – during treatments, or sit comfortably in any position, even while lying down," Shockley said. 

A recent clinical study — conducted by Dr. Konrad Schultz at the Bad Reichenhall Clinic in Munich, Germany — reveals that AffloVest substantially improves cough productivity, making it easier for patients to clear their lungs and breathe more easily through a productive cough.
The study concluded: 

"With every single patient, a dramatic improvement in cough productivity and bronchial secretion viscosity was observed in combination with the pulmonary and orthopedic regimen of care. It became fundamentally easier for the patients to cough out mucus, because of the more fluid secretions and more productive cough provided by the introduction of High Frequency Chest Wall Oscillation treatment with the AffloVest."

Weighing approximately 10 pounds, AffloVest is the lightest and most quiet device of its kind on the market today. Unlike other respiratory vest options, AffloVest provides adjustable levels of treatment intensity and multiple treatment modes. Doctors and patients can tailor their treatments to their needs, with settings that provide chest wall oscillation treatment on both the front and back of the vest.

The number of patients who can benefit from AffloVest is significant; for example, more than 10 million people in the United States currently live with COPD, according to the Centers for Disease Control.

AffloVest is available for Medicare and private health insurance reimbursement under the following Healthcare Common Procedure Coding System (HCPCS) code:

E0483 High Frequency Chest Wall Oscillation AffloVest is now available in five sizes – XS, S, M, L, XL – to serve both children and adults with chronic lung conditions.

AffloVest requires a physician's prescription and is available to U.S. patients through Durable Medical Equipment (DME) and Home Medical Equipment (HME) retailers.

About International Biophysics CorporationInternational Biophysics Corporation (IBC) is a privately held company that develops, manufactures, and sells a variety of complex medical devices. IBC's design and development capabilities include: CAD drawings/CAD interface, prototype development, initial product testing, tooling, mold design and manufacture, validation testing, and FDA submission. IBC is an ISO 13485 certified manufacturing company registered with the FDA, and is based in Austin, Texas. The distribution arm of IBC sells equipment and supplies ranging from centrifugal heart pumps, aortic punches, and blood suctioning wands. Its research and development team has also been involved in Portable Oxygen Concentrator development, dermatological laser devices, and other projects in various medical industries.Related Links:

www.AffloVest.comwww.biophysicscorp.com 

Media Contact:

Lisa Lawrencellawrence@salaspr.com512-426-4904


'/>"/>
SOURCE International Biophysics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idecs Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis
2. World Molecular Imaging Congress to Feature Scientific Breakthroughs in Molecular Multimodal Imaging Essential to Precision Medicine
3. Online Nominations for 2014 Breakthrough Prizes in Life Sciences are Open
4. Start-up Seeks Crowd Funding to Complete Clinical Studies Supporting Breakthrough Blood Test for Earlier Detection of Melanoma
5. Facebook and Twitter Drive Frenzy for Breakthrough "Anti-Aging Pill"
6. Tisch MS Researchers Announce Breakthrough in Disease Monitoring
7. HemoShear Co-Founder Presents Recommendations for Funding of Breakthrough Technologies to U.S. House of Representatives Committee on Science, Engineering and Technology
8. AlignMeds Breakthrough Garment Technology Gets a YES from the FDA!
9. Orthocare Innovations Once Again Recognized for Top Honors for its Breakthrough Prosthetic Foot Ankle System
10. New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix
11. Zydus Pioneers a Breakthrough With LIPAGLYN, Indias First NCE to Reach the Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... -- The global flow cytometry market ... 2025, according to a new study by Grand View ... cancer is expected to upsurge the demand for flow ... years. In addition, higher number of physicians is inclined ... therapy, due to adverse effects caused by chemotherapy & ...
(Date:3/27/2017)... 2017 Summary This report ... and its partnering interests and activities since 2010. Description ... in-depth insight into the partnering activity of one of the ... reports are prepared upon purchase to ensure inclusion of the ... The report will be delivered in PDF format within 1 ...
(Date:3/27/2017)... 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology ... toxicology and efficacy studies. The company is harnessing the ... protein, MAGE A, in an effort to find a ... After 4 weeks of treatment in transgenic mice, ... toxicity in a full toxicology report of various organs. ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 2017 , ... The Radiology Business Management Association (RBMA) is pleased ... new executive director. Mr. Still was selected through a careful months-long search by the ... is known to our members, has been a part of building the RBMA since ...
(Date:3/28/2017)... ... 28, 2017 , ... Award-winning medical group Allied Anesthesia today ... board chair for Orange County health care system CalOptima Friday. CalOptima announced its ... chair Mark Refowitz’s term, which runs through June 30 of this year, until ...
(Date:3/28/2017)... Lithuania (PRWEB) , ... March 28, 2017 , ... ... technologies, today announced the release of two biometric time and attendance tracking products: ... Attendance 4.0 software. NCheck Cloud Bio Attendance uses biometric face recognition to ...
(Date:3/28/2017)... ... March 28, 2017 , ... METTLER TOLEDO Process Analytics is ... plant water and steam. , Chlorides and sulfates cause pitting and stress corrosion ... maintenance and unplanned shutdowns. Monitoring these ions at low ppb levels has therefore ...
(Date:3/28/2017)... ... ... The Executives, Staff & Clients of MGE: Management Experts joined forces with ... Campaign at their Semi-Annual Graduation and Fundraiser Event at MGE’s St. Petersburg Office. , ... 14 internationally in literacy. Statistically, a direct relation can be a found between illiteracy ...
Breaking Medicine News(10 mins):